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Abstract 
Approximately 10-20% of inflammatory bowel disease (IBD) cases are diagnosed beyond 60 years of 
age. Due to the high prevalence of conditions mimicking IBD at older age including NSAR bowel 
disease, diverticulitis, microscopic colitis differential diagnosis of IBD among senior adults is frequently 
delayed.  
Late-onset IBD is characterized by predominance of colonic disease and an overall milder disease 
course with rarer disease progression or new intestinal manifestations. However, senior patients are 
less able to tolerate inflammation and their risk of mortality with severe disease is increased. 
Management of late-onset IBD has been insufficiently studied since senior adults are 
underrepresented in clinical trials and specific problems of older patients such as incontinence 
have not been addressed. To date, treatment generally follows the same principles as in the 
younger. However, older patients are at higher risk for severe adverse effects of the disease and its 
treatments, including bone and muscle loss, infections and lymphoma. Therefore, the safety profile of 
a given drug is of paramount importance in senior IBD patients. Colectomy with ileo-anal pouch 
anastomosis for refractory ulcerative colitis can be performed safely, although functional results may 
be inferior compared to middle-aged patients. To decrease mortality among senior patients, a timely 
surgical intervention is important.  
Late-onset IBD patients develop colorectal carcinoma frequently within the first 8 years after IBD 
diagnosis; therefore, colorectal cancer screening immediately after diagnosis should be 
considered. Further, clinical care for senior IBD patients needs to extend to overall health including 
nutrition, vaccination, bone, muscle and mental health. 
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Introduction 
Crohn`s disease (CD) and ulcerative colitis (UC) are manifestations of chronic intestinal inflammation. 
Awareness of inflammatory bowel diseases (IBD) in senior adults has been increasing and a number of 
reviews addressed this subject [1-8]. The definition of „senior adults“ or “elderly” varies between ≥50 
and ≥65 years; however, a cut-off of 60 years has been most commonly used [2].  
IBD in senior patients comprises senior patients with a new IBD diagnosis (“late-onset IBD”) and 
patients with juvenile or adult onset IBD reaching advanced age. Most systematic studies focus on late-
onset IBD and senior patients with long-standing IBD remain poorly studied. Due to the imminent 
demographic change with a growing segment of senior adults, a significant rise in older IBD patients is 
expected [2]. 
Today, 10-20% of new IBD diagnoses occur in senior adults age >60 years [2, 9]. Population based 
studies found a worldwide incidence of 4-6 per 100,000 per year in CD and 5-8 per 100,000 per year 
UC in adults >60 years [10, 11]. A recent Dutch population based cohort reported even higher numbers 
with an increase of late-onset IBD from 11.7 to 23.7 per 100.000 between 1991 and 2011 [12].  
A bimodal age distribution with a first peak at approximately 25 years and a second peak beyond 60 
years has been reported for the incidence of CD and UC in population-based studies and hospitalization 
statistics [13-15]. These two peaks might reflect exposure to two different categories of IBD risk factors 
[13]. However, only a third of all studies confirmed such a bimodal distribution [11] and 
misclassification of IBD might contribute to late-onset IBD [1].  
 
Presentation and clinical course 
Late-onset IBD is characterized by a predominance of colonic disease and a generally milder 
presentation [8, 16, 17]. In line with colonic predominance, for individuals with IBD, older age is 
associated with the diagnosis of UC [18]. For UC, left-sided disease was more frequent than the more 
severe pancolitis (OR: 1.5) [2]. 
In keeping with colonic predominance, late onset CD more likely manifests as colonic disease (OR 2.6, 
CI: 1.9-3.5) and less likely as ileocolonic (OR 0.43) [2]. Late-onset Crohn’s disease is associated with a 
benign inflammatory disease course; a penetrating (fistulizing) course was less frequently observed 
(OR: 0.48) [2]. Perianal involvement was also less frequently described (OR 0.64) in most [2, 12, 19] but 
not all studies [16].  
Late IBD is typically non-progressive: An increase in disease extent over time was observed in only 16% 
of UC patients in a French population based cohort [16], compared to almost 50% progression in 
pediatric cohorts [3]. Similarly, no new intestinal manifestations occurred in 92% of patients with CD 
over time [16].  
The prognosis of late-onset IBD is controversial and initial studies reporting increased mortality have 
been challenged. One illustrative study from a tertiary care hospital reported a higher rate of steroid 
free-remission at 1 year in UC patients ≥50 years compared to younger individuals (64% vs. 49%) [20]. 
However, hospitalized senior IBD patients remain a high risk population with a higher mortality 
compared to younger patients (OR 3.9), even after adjusting for co-morbidities [21].  
Fecal incontinence predominantly affects senior IBD patients and can greatly affect performance, self-
esteem and quality of life. Fecal incontinence was reported in 20%-25% of patients with IBD [22, 23]; 
however, in a survey as many as 74% of respondents reported some degree of incontinence [24]. Risk 
factors for incontinence include older age, female gender, liquid stools, perianal disease and previous 
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colorectal and perianal surgeries but not IBD diagnosis (UC or CD) [22-24]. Therefore, in senior adults 
with IBD and mild intestinal inflammation, stool incontinence might be the predominant symptom. 
Notably, stool incontinence is frequently not mentioned by patients and active inquiry is advisable. 
Further, abdominal pain might be reported less frequently in senior IBD patients [16]. 
 
Differential diagnosis 
The diagnostic delay for CD is 6 years in senior adults compared to 2 years in younger individuals [10]. 
This difference might be caused by a high number of alternative diagnoses with a high incidence in 
senior adults including diverticulitis, microscopic colitis, ischemic bowel disease, non-steroidal anti-
inflammatory drug (NSAID)-associated colitis and infectious colitis including Clostridium difficile colitis 
[1, 9, 25]. This high number of differential diagnoses represents the most likely explanation for the 
high rate of misdiagnoses of IBD at initial presentation (60% vs. 15% in younger patients) [1]. 
 
Pathophysiology 
IBD pathophysiology likely comprises yet poorly characterized interactions of genetic changes and 
environmental factors with the gut microbiota and the intestinal immune system (Figure 1). In young 
IBD patients, genetic factors are of greater importance than in senior patients [17, 26, 27]. In a French 
population-based study, a family history of IBD was presented in 13% of patients <17 years vs. 3% of 
individuals >60 years [16]. Among CD patients, individuals with the highest genetic risk developed CD 
5 years earlier than individuals with the lowest risk [28].  
Vice versa, in senior IBD patients, environmental factors are likely of paramount importance. Smoking 
is the best-studied environmental factor in IBD and quantitative tobacco smoke exposure is a strong 
risk factor for severe disease with multiple surgeries in CD patients [29]. In contrast, smoking cessation 
is a risk factor for UC and a severe disease course. In Switzerland, overall smoking rates of IBD patients 
paralleled the Swiss population with a higher fraction of smokers in CD than UC (40% vs. 15%) [30]. 
Smoking rates tend to decrease in the general population and significant fraction of senior adults will 
have succeeded in smoking cessation, potentially explaining a fraction of elderly-onset UC cases [20]. 
Exposure to height >2000 m or long-term air travel have been suggested as risk factors of an IBD flare 
[31] and might be more prevalent in the younger. Additional environmental factors with differential 
exposures in senior IBD patients include NSAID, antibiotics, diet, vitamin D, sleep, hygiene and air and 
water pollution [32].  
The gut microbiota undergoes profound changes upon aging, and age-dependent microbiota changes 
have been associated with frailty [33-35]. Moreover, recent antibiotic therapies were risk factors for a 
subsequent IBD diagnosis in adult and pediatric patients with the highest risk in individuals with 
multiple antibiotic therapies [36-38]. Senior patients are at risk for both, recent antibiotic treatment 
and high lifetime cumulative antibiotic exposure. These iatrogenic microbial alterations might result in 
an imbalanced microbiota composition (“dysbiosis”) as a pre-requisite for IBD [36, 37]. Age-dependent 
changes in physiology with lower intestinal motility with slower transit time, constipation and fecal 
retention, shifts in gastric pH, decreased nutrient intake and lower physical activity might also 
contribute to dysbiosis [4].  
Immunosenescence, referring to age-dependent changes in the immune system, is most pronounced 
in the adaptive immune system[39]. Upon regression of the thymus, the number of naïve T cells and 
the diversity of the T cell receptor repertoire decreases. This results in a lower plasticity of the immune 
system and a decreased response to infection [40]. On the other hand, the number of terminally 
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differentiated (“senescent”) T cells increases. These cells are activated by autologous antigens or 
microorganisms including cytomegaly virus [41]. Similarly, in the B cell system antibody production and 
response to antigens are reduced, accompanied by an increase of antigen-experienced, terminally 
differentiated and pro-inflammatory (senescent) B cells [42].  
Immunosenescence also includes pro-inflammatory changes in the innate immune system with a 
higher number of neutrophils and changes in the natural killer cell system [40, 42]. The contribution of 
the pro-inflammatory state of the aging immune system (“immune-aging”) to IBD pathogenesis is not 
understood but remains a potential target for future IBD therapies for senior patients.  
 
Treatment 
IBD treatment for senior patients follows the same principles as treatment for the younger and no 
specific guidelines exist [43-45] (Figure 2). Several key points need to be emphasized: i) Less systematic 
knowledge is available since seniors adults have been systematically excluded from clinical trials [9]. ii) 
Senior patients are less able to tolerate severe and lasting inflammatory IBD activity. In addition, 
elderly patients iii) will more likely experience complications from IBD including thromboembolism and 
cancer, iv) are more likely to experience side effects of any treatment and v) co-morbidities and drug-
drug interactions limit therapeutic options. 
Balancing benefits and safety issues of any treatment is a specific challenge during the care of senior 
patients. Due to the more benign clinical course and the low likelihood of disease progression, 
prognostic interventions for IBD are much less of a concern in senior adults. Therapy should instead 
focus on immediate medical needs and functionality in the activities of daily living. 
In senior patients, comorbidities and polypharmacy are prevalent with an increased risk for drug-drug 
or drug-disease interactions (Table 1) [5, 43, 46]. In one study, IBD patients ≥65 years were treated 
with an average of 9 different medications. 74% of individuals were at risk for potential medication 
interactions including 40% with interactions with IBD medication [47].  
Age-dependent changes in liver and renal function and body composition can also impair 
pharmacokinetics. Volume of distribution of substances can be altered by age-related increase of body 
fat and reduction of total body water, lean muscle mass and hypoproteinemia. Decreased liver and 
renal function in the elderly increase the risk for accumulation of drugs and metabolites. For instance, 
the systemic bio-availability of budesonide of 10-15% is increased in senior adults with a higher 
likelihood of systemic adverse effects [48].  
Susceptibility to specific adverse drug reactions can be increased in senior patients due to co-
morbidities such as metabolic syndrome or cardiovascular diseases (Figure 2, Table 1). Infections in 
seniors under immunosuppressive therapy can take a more serious clinical course and due to age-
related alterations of natural barriers and immune-aging (see above). Long-term immunosuppressive 
treatment contributes to malignancy [49] including non-melanoma skin cancer [50] or hematologic 
malignancies, such as lymphomas [51].  
 
Aminosalicylates 
Oral and topical 5-Aminosalicylic acid (5-ASA) are highly effective as an induction and maintenance 
therapy for UC [43, 52, 53]. In contrast, 5-ASA in the treatment of CD is less effective for maintenance 
of remission . In a recent population based French cohort study, 5-ASA was the most frequently 
prescribed IBD treatment for the elderly and 80% of CD as well as 84% of UC patients had been treated 
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with 5-ASA within 10 years after diagnosis [16, 17]. Overall, 40-60% of senior UC patients adhere to 5-
ASA treatment [4]. The high frequency of 5-ASA use in senior adults might be explained by excellent 
tolerability and limited safe alternatives. Pill size and number as well as problems with self-
administration of suppositories, enemas and foams limit 5-ASA usage in some patients [43, 56].  
 
Corticosteroids  
Corticosteroids are usually required for the induction of treatment in UC, not responding to 5-ASA and 
moderate to severe flares of CD. In population based studies, 47-63% of senior CD patients and 40-
58% of senior UC patients received systemic steroids within 5-10 years after diagnosis [12, 16, 17, 57]. 
However, steroids are limited by dose- and duration-dependent adverse effects such as osteoporosis 
and sarcopenia, contributing to frailty and loss of autonomy among senior patients. In Swiss IBD 
patients, steroids (OR 4.4) and age (OR 1.03 per year) were the most relevant risk factors for decreased 
bone mineral density [17, 58].  
 
Thiopurines  
Immune-suppressive thiopurines (azathioprine and 6-mercaptopurine) are frequently used in elderly 
IBD patients (31-60% in CD, 15-25% in UC, respectively [12, 16, 57]). Side effects include dose-
dependent myelosuppression, necessitating regular blood tests every 3 months. Treatment of gout 
with allopurinol/ febuxostat severely exacerbates this risk [59]. Use of thiopurines >1 year increases 
the risk of malignancies such as lymphoproliferative disorders (HR 6), non-melanoma skin cancer (HR 
2.5-7) and bladder cancer in males (HR 6) [49]. Age (OR 1.8 per decade) and male gender (OR 4.1) are 
additional risk factors for lymphoma [60]. Combination of thiopurines with tumor necrosis factor 
(TNF)-inhibitors further exacerbates lymphoma risk (HR 2.35) including aggressive hepatosplenic T-cell 
lymphoma [43, 51, 61-63]. However, despite the risk of malignancy, thiopurines are appropriate for 
senior patients with moderate-to-severe IBD but continuation of therapy should be evaluated after 1 
year [43]. Methotrexate might be an alternative but no specific data for senior IBD patients are 
available.  
 
Tumor necrosis factor (TNF)-inhibitors 
TNF-inhibitors are a cornerstone of contemporary IBD therapy. Benefits include induction of remission, 
improved quality of life and decreased hospitalizations or surgery. Whether senior patients respond 
differently to TNF-inhibitors remains unclear. Two studies reported older age as a significant risk factor 
for suboptimal response [64, 65]. Furthermore, rates of discontinuation of therapy were two-fold 
higher in senior IBD patients [66].  
Older age is also a significant predictor for severe adverse events upon anti-TNF treatment. In patients 
older than 65 years, the incidence of severe infections and total mortality was 11% and 10%, 
respectively, compared to 2.6% and 1% in younger patients [43, 67]. Co-morbidities, such as severe 
liver disease, hematological disorders and congestive heart failure, also limit usage of TNF-inhibitors. 
Perhaps not surprisingly, TNF-inhibitors were rarely used in senior IBD patients with cumulative 
treatment rates of 5% in CD and 2% in UC over a 5-year observation period in population-based cohorts 
[16, 57]. However, a Dutch cohort reported higher treatment rates of 34% in CD and 9% in UC [12].  
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In summary, for senior patients with moderate-to-severe CD or UC, TNF-inhibitors are an effective 
treatment option with an acceptable safety profile, provided continuous monitoring for infection and 
other adverse effects can be provided [43, 68]. 
 
Integrin inhibitors 
Inhibitors of integrin α4β7, such as vedolizumab, prevent homing of immune cells into the intestine. 
Vedolizumab is effective for induction and maintenance of remission in CD and UC. In line with the gut-
specific mechanism, the safety profile of vedolizumab is excellent with a modest increase of gut and 
upper airway infection rates as the main adverse effects. Studies of vedolizumab included only low 
numbers of individuals >55 years (130 out of 895 participants; 15%), but a recent post-hoc analysis 
reported safety of senior adults included in these trials [69]. Provided future trials confirming safety 
and effectivity for the elderly, integrin inhibitors might become the treatment of choice in this patient 
group. 
 
Ustekinumab 
Ustekinumab has recently been introduced for the treatment of CD [70]. Specific data for the elderly 
are lacking; however, the excellent safety profile renders ustekinumab a promising drug for senior 
adults. 
 
Cyclosporine 
Cyclosporine is a rescue treatment for severe or fulminant disease in IBD patients. Due to adverse 
effects including renal insufficiency and infection for which the elderly are at higher risk, cyclosporine 
remains an option of last resort in senior adults [43]. 
 
Surgery 
Surgery represents a key element of IBD therapy in patients with failure of or intolerance to medical 
treatment. Population based cohort studies of senior IBD patients reported surgery rates of 32-33% 
for CD and 8% for proctocolectomy in UC [12, 16]. In a Canadian study surgery rates were 24% in CD 
and 12% in UC upon 5-year follow-up [71]. 
In UC, proctocolectomy with ileo-anal pouch anastomosis is now the surgical treatment of choice for 
young and senior adults. Even though 90% of elderly UC patients are overall satisfied with the surgical 
outcome [72], results are less favorable beyond age 65 compared to younger individuals [7]. After 
surgery, senior adults experience higher rates of incontinence, pouchitis and anastomotic strictures [7, 
73]. The mortality of elderly UC patients undergoing elective surgery is now <3% [74]; however, 
adequate patient selection and education remain critical [1]. Treatment principles for CD surgery do 
not differ in young and older individuals but the probability of disease recurrence rates after CD surgery 
is controversial [1, 75]. 
Timing of surgical treatment is decisive in IBD patients [1, 75] and delaying surgery is poorly tolerated 
in senior adults. Mortality upon emergent UC surgery can be as high as 27% [8, 76]. Therefore, age 
should not be a reason to delay surgery. 
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Healthcare maintenance 
Healthcare maintenance comprises interventions to prevent illness and promote fitness and health. In 
IBD patients, several preventive interventions are recommended (Table 2) [77-79]. However, in one 
British American study, IBD patients received preventive services at a lower rate compared to control 
individuals [80]. Clear communication between patient, primary care physician and gastroenterologist 
about these shared responsibilities might improve the frequency of vaccination and other effective 
interventions in elderly IBD patients [78].  
Symptoms of depression and anxiety are prevalent in 22% and 35% of IBD patients, respectively [81].  
Psychotherapy and pharmacotherapy are efficient also in IBD patients [82]. Depression is more 
common in senior adults but frequently goes undetected even though treatment options exist [83]. 
Therefore, informal or formalized screening regarding quality of sleep, mood, anxiety, energy level and 
ability to experience joy is strongly advised.  
Osteoporosis and osteoporotic fractures are increased by 40-60% in IBD patients [84, 85]. Senior IBD 
patients are at increased risk of osteoporosis and related fractures due to malnutrition, vitamin D 
deficiency and reduced physical activity [58, 86]. Given this risk profile in addition to age-related bone 
loss, Dual Energy X-ray Absorptiometry (DXA)-screening among senior IBD patients with steroid 
exposure and/or additional risk factors is recommended [52, 86]. However, recent data indicate an 
inconsistent implementation of osteoporosis screening and treatment even in countries with a 
developed health-care system [87].  
Malnutrition is more prevalent in IBD patients >65 years compared to the younger [21]. In addition, 
deficiency of vitamin D (11% in CD, 18% in UC), vitamin B12 (18% CD, 17% UC) and iron (13% CD, 20% 
UC) were found in senior IBD patients in an illustrative study [88]. Therefore, an annual assessment of 
diet, body weight and a laboratory including albumin, ferritin, 25-hydroxyvitamin D and vitamin B12 is 
warranted [77]. 
 
Colorectal cancer screening 
IBD can be complicated by malignancy and most malignancies and malignancy-related deaths occur in 
patients ≥65 years [49, 75]. Colorectal cancer (CRC) screening is advised in all individuals beyond age 
50. However, for IBD patients, a first screening colonoscopy is recommended 8 years after onset of IBD 
symptoms [89]. However, in a population-based Dutch study, in senior patients 35% of CRC cases 
developed within 8 years after IBD diagnosis, before the recommended onset of screening. Age at 
diagnosis was a significant risk factor for these early-onset CRC (HR 2.25 for 10-year older age) [90]. 
Furthermore, a large study form Hong Kong described a much shorter interval to diagnosis of flat 
dysplasia in late-onset IBD patients (1 years vs. 8 years in younger patients) [91]. These data illustrate 
a specific risk for CRC in elderly-onset IBD patients and an additional screening colonoscopy 1-2 years 
after onset of IBD symptoms seems warranted. Surveillance colonoscopies at high frequencies should 
subsequently be performed in individuals with risk factors including family history of CRC, severe and 
extensive colitis, past dysplasia or primary sclerosing cholangitis (PSC) [89]. 
 
Conclusion 
In summary, late-onset IBD comprises 10-15% of all IBD patients. While the disease course remains 
generally mild, a minority of high-risk patients with severe disease exists which requires aggressive 
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management. Challenges include an accurate diagnosis, a patient centered symptom directed therapy, 
and healthcare maintenance issues such as cancer surveillance.  
 
Methods 
Search strategy: We performed a Medline search with the following strategy: (IBD OR inflammatory 
bowel disease OR Crohn’s disease OR Crohns disease OR Morbus Crohn OR ulcerative colitis OR Colitis 
ulcerosa) AND (older people OR elderly OR elderly-onset OR elderly onset OR old patient OR elderly 
patient OR IBD in elderly OR IBD in older patient OR IBD in old patients) AND (management OR 
differences OR treatment OR therapy OR physiology OR phenotype OR guideline); The search was 
limited to English language with a publication date after 2006 and filtered for Clinical Trials, Reviews, 
Guidelines, Meta-analyses, and systematic reviews. Another Medline search using identical search 
terms with less limitations regarding type of article (only excluding case reports) was performed for 
the years 2016 and 2017.  
Our search revealed 1547 publications which were screened. All articles potentially providing 
information regarding epidemiology, pathophysiology, clinical presentation and management of IBD 
in the elderly were retrieved and screened for relevance (207 articles). Due to space limitations only 
26 articles were finally used and quoted in the manuscript.    
 
Author contributions 
 
MB and BM designed the review and wrote the first draft of the paper, LB, MS, GR, SW and HBF 
revised the paper for important intellectual content. All authors approved the final version of the 
manuscript.  
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Tables and Figures 
 
Drug class / 
category 
Substances Common drug 
reactions 
Severe adverse 
reactions 
Drug-drug 
interactions 
Precautions and 
recommendations 
in specific 
susceptible 
populations 
Aminosalicylate 5-aminosaliclic 
acid (5-ASA, 
mesalamine) 
- Abdominal pain, 
diarrhea, nausea, 
vomiting, 
arthralgia, 
asthenia 
- Renal 
impairment, 
gastrointestinal 
hemorrhage, 
cytopenia, 
pancreatitis 
- NSAID: increased 
risk of bleeding 
- Thiopurines: 
increased risk of 
myelosuppression 
- Monitoring of 
laboratory 
parameters (blood 
count, renal function 
Corticosteroids Prednisone 
Budesonide 
(better 
tolerated due to 
first path effect 
in liver) 
- Osteoporosis, 
hypertension, 
impaired glucose 
tolerance  
- Impaired wound 
healing, Cushing’s 
syndrome, 
gastrointestinal 
perforation, 
aseptic necrosis of 
bones, risk for 
infections, adrenal 
insufficiency, 
glaucoma, 
depression, 
delirium 
- More pronounced 
adverse events in 
senior patients 
- NSAID: increased 
risk of gastrointestinal 
bleeding 
- CYP3A4 inhibitors: 
concentration and 
effect increased with 
risk of e.g. Cushing’s 
syndrome, 
hypertension, adrenal 
suppression 
- Quinolones: risk of 
tendon rupture 
 
- Gradual dose 
reduction if risk for 
adrenocortical 
insufficiency 
- Aim for usage <3 
months 
- Clinical monitoring 
(blood pressure, 
myopathy, 
ophthalmological) 
- Laboratory 
monitoring (glucose) 
- Osteoporosis 
screening using 
bone densitometry 
- In senior patients 
close monitoring is 
advised 
Thiopurines Azathioprine 
6-
Mercaptopurine 
- Nausea, vomiting 
- Hematotoxicity, 
hepatotoxicity, 
infections, 
pancreatitis, 
malignancy risk 
(especially in 
senior patients) 
- Allopurinol, 
febuxostat: increased 
thiopurine toxicity with 
severe 
myelosuppression. 
Combination only 
under strict 
restrictions and 
surveillance! 
- ACE inhibitors: 
myelosuppression 
- Yearly screening 
for dermatologic 
malignancies 
- Monitoring of 
laboratory 
parameters: blood 
count, liver function 
test (e.g. 1 month 
after dosage 
change, 3 months) 
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- Echinacea: 
decreased 
effectiveness of 
thiopurines 
- Hypersensitivity 
cross-reaction 
between different 
thiopurines 
- Close monitoring in 
senior patients 
Calcineurin 
inhibitor 
Cyclosporine - Hypertension, 
gingival 
hyperplasia, 
tremor 
- Hepatoxocity, 
nephrotoxicity, 
infections  
- poorly tolerated 
in senior patients 
- Selected statins: 
contraindicated due 
to increased risk of 
myopathy and 
rhabdomyolysis 
- NSAID: 
nephrotoxicity 
- CYP3A4 inhibitors: 
increased 
cyclosporine 
concentrations and 
toxicity 
- TNF-inhibitors: 
decreased 
concentrations, 
reduced effectiveness 
- Close therapeutic 
drug monitoring in 
combination with 
CYP inhibitor/ 
inducer 
- Monitoring of drug 
levels and renal 
function 
- Extreme caution in 
senior patients 
TNF-inhibitors Infliximab 
Adalimumab 
Golimumab 
Certolizumab 
- Headache, 
fatigue, upper 
respiratory 
infections, rash, 
nausea 
- Anaphylaxis, 
opportunistic 
infections, 
malignancy, 
autoimmune 
hepatitis, acute 
liver failure, heart 
failure 
- Other 
immunosuppressants: 
increased risk for 
infections and 
malignancy 
(especially in senior 
patients) 
- Tuberculosis 
(tuberculin skin test 
(TST) and/or 
interferon-gamma 
release assay 
(IGRA),) and HBV 
testing prior to 
initiation 
- Avoid in heart 
failure; worsening of 
symptoms possible 
- Laboratory 
monitoring (blood 
count, liver function 
tests) 
- Caution in senior 
patients 
Integrin 
inhibitors 
Vedolizumab - Arthralgia, 
nausea, upper 
respiratory 
infections, fatigue 
- Hepatitis, 
anaphylaxis, PML, 
infections 
- TNF-inhibitors, cave 
with combination due 
to potentiation of 
immunosuppression 
- Echinacea: 
decreased 
effectiveness of 
vedolizumab 
- Live vaccination 
prior to initiation 
- Laboratory 
monitoring (liver 
function) 
Anti-IL12 and 
anti-IL23 
Ustekinumab - Upper respiratory 
and urinary tract 
- TNF-inhibitors: cave 
with combination due 
Live vaccination, 
(e.g.  BCG <1 year 
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monoclonal 
antibody 
infections, fatigue, 
headache, 
vomiting 
- Skin cancer, 
anaphylaxis, 
PRES, serious 
infections 
to potentiation of 
immunosuppression 
 
prior to initiation, 
during, or <1 year 
after discontinuation 
of ustekinumab is 
not recommended 
 
 
Table 1. Drug classes, example of substances, selected adverse drug reactions and drug-drug 
interactions pronounced in the elderly.  
CYP3A4 inhibitors: Cytochome P450 isoenzyme 3A4 inhibitors: ciprofloxacin, clarithromycin, 
erythromycin, fluconazole, itraconazole, posaconazole, voriconazole; fluvoxamine; amiodarone, 
ceritinib, cobicistat, cyclosporine, darunavir. CYP3A4 inducers exhibit opposite effects with reduced 
substrate concentrations and effectiveness. HBV hepatitis B virus. PML progressive multifocal 
leukoencephalopathy. PRES posterior reversible encephalopathy syndrome. BCG Bacillus Calmette-
Guierin. TNF: tumor necrosis factor. ACE: angiotensin converting enzyme. IL: Interleukin  
Butter et al., IBD in older adults 
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Intervention Comments 
Vaccination Follow guidelines for elderly individuals 
• Influenza, pneumococcal, herpes zoster 
vaccines among others 
Avoid life vaccines in the immune-
suppressed patient* 
Colorectal cancer screening Colonoscopy screening every 10 years, 
starting at age 50 years. Additional 
screening should be considered in high-risk 
individuals. Elderly-onset IBD patients might 
be a high-risk population for CRC and 
additional screening starting 1-2 years after 
diagnosis should be considered.  
Skin cancer screening In immune-suppressed individuals yearly 
skin inspection by dermatologist 
Mental health Structured inquiry regarding 
• Quality of sleep 
• Mood, level of energy 
• Did patient stop enjoying pleasant 
activities 
Bone health In IBD patients with long and/ or severe 
inflammation and/ or steroid usage or 
additional risk factors 
• DXA scan 
• If appropriate calcium and vitamin D 
supplementation 
Malnutrition Informal inquiry about nutrition, eating 
habits 
Documentation of weight at regular intervals 
Measure albumin, ferritin, vitamin D, vitamin 
B12 and folic acids at least yearly 
Smoking cessation High benefits also for senior patients 
Regular counselling, refer to smoking 
cessation program 
Senior patients: Less likely to start quitting, 
but higher changes for success  
 
Table 2: Health maintenance in senior IBD patients, recommended interventions and comments.  
*Live vaccines include: adenovirus, rotavirus, Bacille Calmette-Guerin (BCG), live attenuated 
(intranasal) influenca, live attenuated poliovirus, measles, mumps, rubella, varicella, zoster, smallpox, 
oral typhoid and yellow fever vaccine.  
 
  
Butter et al., IBD in older adults 
 
14 
Figure Captions 
 
Figure 1: Risks and relevant physiological changes in senior IBD patients. 
Figure 2: Overview of therapeutic options for elderly IBD patients. 
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